Thus, antagonizing PPARδ to correct metabolic abnormalities in lesional atopic dermatitis and psoriasis plaques might be a new and effective therapeutic strategy to reduce both epidermal hyperplasia and consumption of structural lipids of the stratum corneum lipid matrix. The gene discussed is PPARD; the disease is atopic eczema.